Bulk Pharmaceutical API Sources for ethchlorvynol

Bulk Pharmaceutical API Sources for ethchlorvynol

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS015903758
Ambinter		Amb13889603
Ambinter		Amb22055189

Bulk Active Pharmaceutical Ingredient (API) Sources for ETHCHLORVYNOL

Last updated: August 1, 2025

---

Introduction

Ethchlorvynol, historically used as a sedative and hypnotic agent, has seen its clinical application diminish due to safety concerns, including potential for abuse and adverse effects. Nonetheless, the ongoing global pharmaceutical and chemical supply chains necessitate awareness of reliable bulk API sources for Ethchlorvynol, whether for generic manufacturing, research, or regulatory-controlled reuse. This report examines the primary sources of Ethchlorvynol APIs, their geographic distribution, regulatory considerations, and the implications for pharmaceutical companies and stakeholders.

---

Chemical Profile and Market Context

Ethchlorvynol (Iupac: 2-ethyl-2-chlorovinyl-3,3-bis(ethoxy)cyclobutanone) was first synthesized in the mid-20th century and manufactured predominantly during the 1950s and 1960s. Its synthesis involves complex multi-step chemical processes, primarily accessible to specialized chemical manufacturers with capabilities in halogenated cyclobutanone derivatives.

Despite its declining medical use, demand for Ethchlorvynol as an API persists in niche research contexts and pharmaceutical manufacturing, especially for formulators seeking generic or alternative sedatives. The market is characterized by limited licensed suppliers and a fragmented supply chain, often influenced by strict regulatory controls, import/export restrictions, and concerns over controlled substance classification [1].

---

Major Sources of Ethchlorvynol API

1. Established Chemical and API Manufacturers in China and India

a. Chinese API Producers

China remains the dominant global supplier of pharmaceutical intermediates and APIs, including Ethchlorvynol, owing to its extensive chemical manufacturing infrastructure. Several state-of-the-art factories, primarily in regions such as Zhejiang, Jiangsu, and Shandong, have the capability to produce high-purity APIs under Good Manufacturing Practice (GMP) standards.

• Key Players:
  • Zhejiang-based chemical companies with custom synthesis capabilities for halogenated cyclobutane derivatives.
  • Shandong-based API producers with historical track records in producing sedative APIs.
• Regulatory Status:
  • Many Chinese API manufacturers operate under GMP licensing aligned with Chinese NMPA standards. Export quality APIs are often compliant with international pharmacopoeias like USP or EP, but due diligence is necessary due to variable regulatory oversight.

b. Indian API Manufacturers

India hosts numerous API manufacturers specializing in controlled substances and complex chemical synthesis. Though less prominent than Chinese counterparts for Ethchlorvynol specifically, some firms offer custom synthesis services, often catering to regional markets.

• Key Players:
  • Companies with expertise in halogenated cyclobutyl intermediates.
  • Firms with capacity for low-volume, high-complexity APIs compliant with WHO-GMP standards.

2. Specialized Chemical Synthesis Firms in Eastern Europe and Southeast Asia

Some smaller firms in Eastern Europe, such as Poland, Bulgaria, and Southeast Asian countries, possess niche capabilities for producing controlled or withdrawn APIs like Ethchlorvynol. These entities typically focus on bespoke synthesis for research needs or legacy pharmaceutical products.

• Considerations:
  • Regulatory scrutiny increases for these sources; verification of GMP compliance and licensing is essential.
  • Supply chains tend to be episodic, with procurement often requiring negotiation through intermediaries.

3. Contract Research and Custom Synthesis Service Providers

In recent years, Contract Manufacturing Organizations (CMOs) offering custom synthesis services have become alternate sources. They may manufacture Ethchlorvynol API in quantities ranging from grams to multi-kilogram batches, primarily for laboratory or research use.

• Advantages:

  • High-quality, verified batches with Certificate of Analysis (CoA).
  • Flexibility in quantity and purity specifications.

• Limitations:

  • Not always suitable for large-scale commercial use due to capacity constraints.
  • Cost premiums and longer lead times.

---

Regulatory and Legal Constraints

Because Ethchlorvynol is classified as a controlled substance in multiple jurisdictions, sourcing and distribution are regulated under international frameworks such as the Single Convention on Narcotic Drugs and national drug control laws. Manufacturers and purchasers must ensure compliance with:

• International Regulations:**

  • WHO scheduling provisions for sedative-hypnotic substances.
  • Import/export permits.

• Country-specific Controls:

  • US DEA schedules, which classify Ethchlorvynol as a Schedule IV substance.
  • EU drug precursor regulations under similarly strict classifications.

Failure to adhere to these legal frameworks can result in severe penalties and loss of licensing privileges. Suppliers typically require proof of legitimate use, registration details, and appropriate documentation.

---

Supply Chain Challenges and Considerations

• Limited Availability: Many suppliers have phased out manufacturing due to declining demand and regulatory scrutiny.
• Quality Assurance: Buyers should verify GMP compliance, batch purity, and CoA documentation.
• Pricing Dynamics: Scarcity drives higher costs; sourcing from less regulated markets may involve legal risks.
• Traceability and Due Diligence: Engage reputable intermediaries, perform vendor audits, and seek transparent supply histories.

---

Emerging Trends and Future Outlook

The future of Ethchlorvynol API sourcing depends on regulatory shifts, regional manufacturing policies, and potential resurgence in research applications. Manufacturers with specialized capabilities in halogenated cyclic compounds might diversify to meet niche demands, but widespread commercial production appears unlikely. Pharmacovigilance and international control measures will continue to influence supply dynamics.

---

Key Takeaways

• Chinese and Indian API manufacturers remain the primary sources for Ethchlorvynol bulk API, with most suppliers offering GMP-quality products tailored for research or controlled pharmaceutical applications.
• Due to its controlled status, sourcing Ethchlorvynol APIs requires adherence to strict legal and regulatory frameworks, including licensing, documentation, and import/export controls.
• Contract synthesis providers play a crucial role in fulfilling specialized, low-volume needs, especially for research purposes.
• Regulatory scrutiny and legal restrictions significantly impact availability, driving market prices and complicating procurement.
• due diligence, certification verification, and legal compliance remain paramount when considering Ethchlorvynol API sourcing.

---

FAQs

1. Is Ethchlorvynol available from licensed pharmaceutical suppliers?
Yes, but availability is limited and tightly regulated; many suppliers operate in China and India under compliance with GMP standards. Due to regulatory classifications, procurement demands significant legal due diligence.

2. Can I import Ethchlorvynol API without proper licenses?
No; Ethchlorvynol is a controlled substance in many jurisdictions, and unauthorized import/export constitutes legal violations. Proper licenses, permits, and documentation are mandatory.

3. Are there reputable third-party synthesis providers?
Yes, especially for research quantities, certain CMOs and custom synthesis firms can produce Ethchlorvynol API with verified purity and documentation, provided ordering complies with legal restrictions.

4. What are the risks associated with sourcing from unregulated or grey markets?
Significant legal risks, potential quality issues, and safety concerns. Such sources often lack transparency, GMP compliance, and proper documentation, risking confiscation or legal penalties.

5. How will regulatory reforms impact Ethchlorvynol API supply?
Changes in international drug scheduling or national regulations could either restrict or ease access, influencing global supply chains and pricing. Continuous regulatory monitoring is essential.

---

References

[1] International Narcotics Control Board. Report of the International Narcotics Control Board for 2022.